Ensysce Biosciences, Inc. 8-K

What Happened
Ensysce Biosciences, Inc. (ENSC) announced it received a notice from the Nasdaq Listing Qualifications Department that it is not in compliance with Nasdaq Listing Rule 5550(b)(1) because its stockholders’ equity was below the $2.5 million requirement as of March 31, 2026. Nasdaq gave the company 45 days to submit a plan to regain compliance (deadline: July 6, 2026). If Nasdaq accepts the plan, the company may receive an extension of up to 180 days from May 21, 2026 to regain compliance; if Nasdaq does not accept the plan the company may appeal to the Nasdaq Hearings Panel.

Key Details

• Nasdaq rule cited: Listing Rule 5550(b)(1) — $2.5 million minimum stockholders’ equity requirement.
• Measurement date: non‑compliance determined as of March 31, 2026.
• Deadline to submit a compliance plan to Nasdaq: within 45 days (by July 6, 2026).
• Possible outcomes: Nasdaq may grant up to a 180‑day extension from May 21, 2026 if a plan is accepted; if not accepted the company can appeal to the Nasdaq Hearings Panel.
• Company action: Ensysce plans to timely submit a plan and will explore options to regain compliance, but stated there is no assurance Nasdaq or the Panel will accept such a plan.

Why It Matters
A Nasdaq delisting notice is material because it puts the company at risk of losing its Nasdaq listing if it cannot demonstrate compliance. That outcome could affect trading, liquidity and investor access to the stock. Investors should watch for the company’s submitted plan, any Nasdaq decision or Panel appeal, and subsequent filings that report whether Ensysce has regained compliance or faces delisting.